Aachen, Germany, Oct 24, 2007 - (Hugin via Asia Business News) - Aachen (Germany), 24 October 2007 - PAION AG (Frankfurt Stock Exchange, Prime Standard: PA8) announced today that it has advanced its anticoagulant Solulin to clinical Phase I by conducting a first-in-man study. Two dosages have already been tested and were well tolerated. PAION's development candidate is an improved recombinant variant of the human protein thrombomodulin. The study is designed to evaluate safety, tolerability and pharmacokinetics of Solulin and to gain information on pharmacodynamics in response to intravenous doses of the substance. It is being conducted as a single-center, randomized, single-blind, placebo-controlled Phase I study in healthy volunteers. Initial results are expected in early 2008.
